Further studies will be required to determine if similar mechanisms are responsible in part for the clinical benefit of IBAT inhibitors that was recently demonstrated in children with progressive familial intrahepatic cholestasis and Alagille syndrome (21, 22). This evidence concerns the gene SLC10A2 and familial intrahepatic cholestasis.